To test this hypothesis, we set out to treat Dyrk1a-KI mice with lithium, bipolar disorder medication known to exert pleiotropic neurodevelopmental, neuroprotective, and neuro-synaptic effects through multiple mechanisms, including GSK3β inhibition [29–36]. The gene discussed is GSK3B; the disease is bipolar disorder.